To systematically evaluate the clinical efficacy and safety of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation.Randomized controlled trials(RCT)on the treatment of senile constipation with Maren...To systematically evaluate the clinical efficacy and safety of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation.Randomized controlled trials(RCT)on the treatment of senile constipation with Maren Runchang Pill(麻仁润肠丸)were searched by computer in CNKI,CBM,WanFang,VIP,PubMed,EMbase and the Cochrane Library databases.The retrieval time limit was from the establishment of the database to May 2019.A total of 2 researchers independently screened literature and extracted data according to the inclusion criteria,and Meta-analyzed the RCT that met the standards by applying RevMan5.3 software.A total of 5 randomized controlled trials were included,including 395 patients with senile constipation,199 in the experimental group and 196 in the control group.The treatment group was treated with Maren Runchang Pill(麻仁润肠丸),while the control group was treated with other Western medicine,including fruit guide tablets,lactulose oral liquid or kaisailu,etc.The results of Meta-analysis showed that there was no significant difference in the total clinical efficacy between Maren Runchang Pill(麻仁润肠丸)and other Western medicines[RR=1.02,95%CI(0.88,1.17),P=0.83].In terms of improvement of abdominal distension and inappetence,there was no significant difference between the treatment with Maren Runchang Pill(麻仁润肠丸)and other Western medicine[RR=1.03,95%CI(0.85,1.24),P=0.78].Maren Runchang Pill(麻仁润肠丸).This study showed that the efficacy of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation was not significantly different from that of conventional Western medicine,and was safe,and effective,with few adverse reactions.Maren Runchang Pill(麻仁润肠丸),as a traditional Chinese patent medicine,can play the role of regulating qi and replenishing blood,and regulating bowel and bowel laxative,with fewer cost.It is more suitable for the elderly to use,with good compliance,and clinically it should be used with syndrome differentiation.However,due to the quantity and quality of the original study,multi-center,high-quality randomized controlled trials are still needed to further confirm it.展开更多
目的基于网络药理学和分子对接法分析麻仁丸治疗便秘的作用机制,为经典中成药的临床应用提供参考。方法通过中药系统药理学数据库和分析平台(TCMSP)获取火麻仁、苦杏仁、大黄、枳实、厚朴、白芍的主要化学成分及其靶点,根据药物代谢动力...目的基于网络药理学和分子对接法分析麻仁丸治疗便秘的作用机制,为经典中成药的临床应用提供参考。方法通过中药系统药理学数据库和分析平台(TCMSP)获取火麻仁、苦杏仁、大黄、枳实、厚朴、白芍的主要化学成分及其靶点,根据药物代谢动力学(ADME)筛选中药活性组分;通过基因信息数据库(Gencards,OMIM and DRUGBANK)获取便秘主要靶点,利用String数据库分析蛋白间的互作关系,构建PPI网络并挖掘核心调控基因,对关键靶点进行富集分析(GO和KEGG)。采用Cytoscape3.8.2软件构建“麻仁丸成分-便秘-通路”网络,最后通过Auto Dock进行分子对接验证。结果麻仁丸治疗便秘的核心活性成分为山奈酚、川陈皮素、芦荟大黄素等,核心靶点有AKT1、IL6、VEGFA、TNF等,治疗便秘的生物学通路主要作用于肿瘤通路、乙肝通路、丙肝通路、AGE-RAGE信号通路以及PI3K/Akt信号通路等。结论本研究初步揭示了麻仁丸治疗便秘的多成分、多靶点、多通路的作用机制,为麻仁丸的临床开发利用提供基础。展开更多
基金Supported by National Key Research&Development Plan(2018YFC1707400,2018YFC1707410)。
文摘To systematically evaluate the clinical efficacy and safety of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation.Randomized controlled trials(RCT)on the treatment of senile constipation with Maren Runchang Pill(麻仁润肠丸)were searched by computer in CNKI,CBM,WanFang,VIP,PubMed,EMbase and the Cochrane Library databases.The retrieval time limit was from the establishment of the database to May 2019.A total of 2 researchers independently screened literature and extracted data according to the inclusion criteria,and Meta-analyzed the RCT that met the standards by applying RevMan5.3 software.A total of 5 randomized controlled trials were included,including 395 patients with senile constipation,199 in the experimental group and 196 in the control group.The treatment group was treated with Maren Runchang Pill(麻仁润肠丸),while the control group was treated with other Western medicine,including fruit guide tablets,lactulose oral liquid or kaisailu,etc.The results of Meta-analysis showed that there was no significant difference in the total clinical efficacy between Maren Runchang Pill(麻仁润肠丸)and other Western medicines[RR=1.02,95%CI(0.88,1.17),P=0.83].In terms of improvement of abdominal distension and inappetence,there was no significant difference between the treatment with Maren Runchang Pill(麻仁润肠丸)and other Western medicine[RR=1.03,95%CI(0.85,1.24),P=0.78].Maren Runchang Pill(麻仁润肠丸).This study showed that the efficacy of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation was not significantly different from that of conventional Western medicine,and was safe,and effective,with few adverse reactions.Maren Runchang Pill(麻仁润肠丸),as a traditional Chinese patent medicine,can play the role of regulating qi and replenishing blood,and regulating bowel and bowel laxative,with fewer cost.It is more suitable for the elderly to use,with good compliance,and clinically it should be used with syndrome differentiation.However,due to the quantity and quality of the original study,multi-center,high-quality randomized controlled trials are still needed to further confirm it.
文摘目的基于网络药理学和分子对接法分析麻仁丸治疗便秘的作用机制,为经典中成药的临床应用提供参考。方法通过中药系统药理学数据库和分析平台(TCMSP)获取火麻仁、苦杏仁、大黄、枳实、厚朴、白芍的主要化学成分及其靶点,根据药物代谢动力学(ADME)筛选中药活性组分;通过基因信息数据库(Gencards,OMIM and DRUGBANK)获取便秘主要靶点,利用String数据库分析蛋白间的互作关系,构建PPI网络并挖掘核心调控基因,对关键靶点进行富集分析(GO和KEGG)。采用Cytoscape3.8.2软件构建“麻仁丸成分-便秘-通路”网络,最后通过Auto Dock进行分子对接验证。结果麻仁丸治疗便秘的核心活性成分为山奈酚、川陈皮素、芦荟大黄素等,核心靶点有AKT1、IL6、VEGFA、TNF等,治疗便秘的生物学通路主要作用于肿瘤通路、乙肝通路、丙肝通路、AGE-RAGE信号通路以及PI3K/Akt信号通路等。结论本研究初步揭示了麻仁丸治疗便秘的多成分、多靶点、多通路的作用机制,为麻仁丸的临床开发利用提供基础。
